Aprogen "Considering Third-Party Allocation Paid-in Capital Increase"
[Asia Economy Reporter Gong Byung-sun] Aprogen announced on the 17th that it is reviewing various funding options, including a third-party allotment paid-in capital increase, to accelerate global clinical trials, aggressive development, and product approvals for its ongoing biosimilar pipeline. However, it stated that no specific plan has been decided yet.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "Jeong Yu-kyung Is a Neighbor"...Itaewon Standalone House with Record 23.2 Billion Won Appraisal Up for Auction [Real Estate AtoZ]
- Samsung and Google Unveil 'AI Glasses'... Effortless Navigation and Translation Without a Smartphone
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
On the same day, some media outlets reported that Aprogen is planning to sell its management rights through a third-party allotment paid-in capital increase.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
